Leriglitazone
As of the edition of 20 October 2026, Leriglitazone is a small molecule: marketed, first approved in 2026 (EU); acts on PPARG.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- Brand name
- Nezglyal
- First approved
- 21 September 2026 (EU)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Minoryx Therapeutics
- Registered trials
- 2, 0 stopped early
- Disease areas
- Inherited and neonatal; Nervous system; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Leriglitazone.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PPARG | Peroxisome proliferator-activated receptor gamma | P37231 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 1 | 0 | 0 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Minoryx Therapeutics | Originator and Lead sponsor of trials | 2019 to now |